MX2009004532A - Composiciones y metodos para unir esfingosina-1-fosfato. - Google Patents
Composiciones y metodos para unir esfingosina-1-fosfato.Info
- Publication number
- MX2009004532A MX2009004532A MX2009004532A MX2009004532A MX2009004532A MX 2009004532 A MX2009004532 A MX 2009004532A MX 2009004532 A MX2009004532 A MX 2009004532A MX 2009004532 A MX2009004532 A MX 2009004532A MX 2009004532 A MX2009004532 A MX 2009004532A
- Authority
- MX
- Mexico
- Prior art keywords
- phosphate
- compositions
- methods
- binding sphingosine
- sip
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con agentes anti-S1P, por ejemplo, anticuerpos monoclonales humanizados, y con sus usos para la detección de S1P o para el tratamiento de enfermedades y condiciones asociadas con S1P.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85497106P | 2006-10-27 | 2006-10-27 | |
PCT/US2007/082647 WO2008070344A2 (en) | 2006-10-27 | 2007-10-26 | Compositions and methods for binding sphingosine-1-phosphate |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004532A true MX2009004532A (es) | 2009-09-04 |
Family
ID=39492938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004532A MX2009004532A (es) | 2006-10-27 | 2007-10-26 | Composiciones y metodos para unir esfingosina-1-fosfato. |
Country Status (18)
Country | Link |
---|---|
US (6) | US7829674B2 (es) |
EP (1) | EP2087002B1 (es) |
JP (2) | JP5795833B2 (es) |
KR (1) | KR101581279B1 (es) |
CN (2) | CN104650225B (es) |
AU (1) | AU2007329759B2 (es) |
BR (1) | BRPI0718118A2 (es) |
CA (1) | CA2667574A1 (es) |
DK (1) | DK2087002T3 (es) |
ES (1) | ES2524059T3 (es) |
IL (1) | IL198379A (es) |
MX (1) | MX2009004532A (es) |
PL (1) | PL2087002T3 (es) |
PT (1) | PT2087002E (es) |
RU (1) | RU2460541C2 (es) |
SI (1) | SI2087002T1 (es) |
WO (1) | WO2008070344A2 (es) |
ZA (1) | ZA200902860B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8614103B2 (en) * | 2006-10-27 | 2013-12-24 | Lpath, Inc. | Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions |
US20140186339A1 (en) * | 2006-10-27 | 2014-07-03 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
US8212010B2 (en) | 2008-02-25 | 2012-07-03 | Expression Drug Designs, Llc | Sphingosine 1-phosphate antagonism |
EP2262528A2 (en) * | 2008-02-25 | 2010-12-22 | Expression Drug Designs, Llc. | Sphingosine 1-phosphate antagonism |
WO2009124294A2 (en) | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
US8401799B2 (en) | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
KR20110097923A (ko) * | 2008-12-05 | 2011-08-31 | 엘파스, 인크. | 항-지질 항체 결정 구조를 이용한 항체 설계 |
EP2400981A4 (en) * | 2009-02-26 | 2013-02-27 | Lpath Inc | DESGIN FOR HUMANIZED THROMBOZYTE ACTIVATION FACTOR ANTIBODIES BY ANTI-LIPID ANTIBODY TEMPLATES |
US20120282654A1 (en) * | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
WO2011031397A1 (en) | 2009-08-06 | 2011-03-17 | Genentech, Inc. | Method to improve virus removal in protein purification |
GB2476681B (en) * | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
WO2011106723A2 (en) * | 2010-02-26 | 2011-09-01 | Lpath, Inc. | Anti-paf antibodies |
WO2011109650A1 (en) * | 2010-03-03 | 2011-09-09 | The Board Of Trustees Of The University Of Illinois | Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists |
WO2011137344A2 (en) | 2010-04-30 | 2011-11-03 | Lpath, Inc. | Anti-s1p antibody treatment of patients with ocular disease |
CA2801890A1 (en) * | 2010-06-06 | 2012-05-03 | Lpath, Inc. | Combinations of anti-s1p antibodies and sphingolipid pathway inhibitors |
US8747844B2 (en) | 2010-07-30 | 2014-06-10 | Saint Louis University | Methods of treating pain |
EP2646047A2 (en) * | 2010-12-01 | 2013-10-09 | Universität Zürich | Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases |
JP5766958B2 (ja) * | 2011-01-21 | 2015-08-19 | オリンパス株式会社 | 顕微鏡システム、情報処理装置、及び情報処理プログラム |
WO2012162392A1 (en) * | 2011-05-23 | 2012-11-29 | Timothy Hla | Endothelium protective materials and methods of use |
EP2742337B1 (en) | 2011-08-19 | 2016-05-04 | Malvern Instruments Ltd | Dual-mode characterization of particulates |
EP2870180B1 (en) | 2012-07-04 | 2024-08-28 | F. Hoffmann-La Roche AG | Anti-biotin antibodies and methods of use |
SI2869848T1 (sl) * | 2012-07-04 | 2017-01-31 | F. Hoffmann-La Roche Ag | Kovalentno vezani konjugati antigen-protitelo |
BR112014030843A2 (pt) | 2012-07-04 | 2019-10-15 | Hoffmann La Roche | anticorpo anti-teofilina, formulação farmacêutica e uso do anticorpo |
GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
EP2787006B1 (en) | 2013-04-02 | 2018-02-28 | Miltenyi Biotec GmbH | Anti-CD8 antibody which binding is Ca2+ dependent |
CN105873615B (zh) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | 共价连接的helicar-抗helicar抗体缀合物及其用途 |
PL3089996T3 (pl) | 2014-01-03 | 2021-12-13 | F. Hoffmann-La Roche Ag | Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg |
RU2682754C2 (ru) | 2014-01-03 | 2019-03-21 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью |
JP6654581B2 (ja) | 2014-06-26 | 2020-02-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗brdu抗体および使用方法 |
WO2016070957A1 (en) * | 2014-11-06 | 2016-05-12 | Merck Patent Gmbh | Activated carbon for the removal of leachables and/or extractables |
US9754383B1 (en) * | 2014-12-22 | 2017-09-05 | Flagship Biosciences, Inc. | Automated methods for assessment of celiac disease |
WO2017015334A1 (en) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
CN105820250B (zh) * | 2016-04-29 | 2019-04-30 | 中国人民解放军第四军医大学 | 一种抗basigin人源化抗体及其应用 |
AU2017376922B2 (en) | 2016-12-15 | 2022-12-01 | Société des Produits Nestlé S.A. | Compositions and methods that modulate phosphorus or enzymes in a companion animal |
US10975167B2 (en) | 2017-04-14 | 2021-04-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase |
WO2018191751A1 (en) | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizonia | Compositions and methods for treating pulmonary fibrosis |
Family Cites Families (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1073471B (de) | 1958-09-02 | 1960-01-21 | Chemische Werke Hüls Aktiengesellschaft, Marl (Kr. Recklinghausen) | Verfahren zur Herstellung von Azelainsäure |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
GB1573212A (en) | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
SE455445B (sv) | 1984-08-28 | 1988-07-11 | Pharmacia Ab | Antikroppar mot sialosyllaktotetraos (iv?723neuaclcose?714) och antikroppens resp antigenets anvendning vid tumordiagnostik |
EP0173648A3 (en) | 1984-08-30 | 1988-04-27 | Ciba-Geigy Ag | New monoclonal antibodies to glycoconjugates, processes for their production, and applications |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4937232A (en) | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
DE3741056A1 (de) | 1987-12-04 | 1989-08-24 | Behringwerke Ag | Manumycin-derivate, verfahren zu ihrer herstellung und ihre verwendung |
WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20030229208A1 (en) | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5248824A (en) | 1990-12-31 | 1993-09-28 | The Biomembrane Institute | Method of preparing N,N,N-trimethylsphingosine |
US5137919A (en) | 1990-12-31 | 1992-08-11 | Biomembrane Institute | Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation |
US5151360A (en) | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
US5677288A (en) | 1991-05-15 | 1997-10-14 | Cypros Pharmaceutical Corporation | Use of aminoglycosides to protect against excitotoxic neuron damage |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5430160A (en) | 1991-09-23 | 1995-07-04 | Florida State University | Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
JP3571337B2 (ja) | 1992-02-11 | 2004-09-29 | セル ジェネシス,インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5260288A (en) | 1992-04-03 | 1993-11-09 | The Biomembrane Institute | Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives |
US5369030A (en) | 1992-09-11 | 1994-11-29 | Duke University | Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US5444087A (en) | 1993-10-19 | 1995-08-22 | Bristol-Myers Squibb Company | Manumycin compounds |
SG49032A1 (en) | 1993-11-15 | 1998-05-18 | Baker Med Res Inst | A method for treating cardiac dysfunction and pharmaceutical compositions useful therefor |
GB9325182D0 (en) | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
ES2149350T3 (es) | 1994-02-02 | 2000-11-01 | Liposome Co Inc | Compuestos y liposomas farmaceuticamente activos y metodos para su utilizacion. |
US5430169A (en) | 1994-02-14 | 1995-07-04 | The United States Of America Represented By The Department Of Health And Human Services | Method for preparation of sphingoid bases |
US5585476A (en) | 1994-02-15 | 1996-12-17 | Maclennan; Alexander J. | Molecular cloning and expression of G-protein coupled receptors |
US5627171A (en) | 1994-04-11 | 1997-05-06 | Oncomembrane, Inc. | Sphingosine-1-phosphate/trimethylsphingosine composition |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
WO1998003529A1 (fr) | 1996-07-19 | 1998-01-29 | Takara Shuzo Co., Ltd. | Procede de preparation de sphingolipides et de derives de sphingolipides |
US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US5667337A (en) | 1995-09-15 | 1997-09-16 | Lazes; Richard J. | Rotating containment and repelling boom and method for confining a material floatable on a liquid surface |
WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
JPH09110722A (ja) | 1995-10-20 | 1997-04-28 | Toray Ind Inc | 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法 |
US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5830916A (en) | 1996-05-23 | 1998-11-03 | Duke University | Inhibitor of ceramidase |
DE19621038A1 (de) | 1996-05-24 | 1997-11-27 | Boehringer Ingelheim Kg | Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten |
US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
US6140060A (en) | 1996-12-12 | 2000-10-31 | Chun; Jerold J. M. | Cloned lysophosphatidic acid receptors |
US5919687A (en) | 1996-12-24 | 1999-07-06 | John Hopkins University | Recombinant N-SMases and nucleic acids encoding same |
US6235912B1 (en) | 1997-03-12 | 2001-05-22 | Takara Shuzo Co., Ltd. | Sphingosine analogues |
DE69842017D1 (de) * | 1997-06-10 | 2011-01-05 | Lpath Inc | Verfahren zum frühzeitigen nachweis herzerkrankungen |
US6740512B1 (en) | 1997-08-11 | 2004-05-25 | Memorec Biotec Gmbh | Neutral sphingomyelinase |
US5989803A (en) | 1997-09-05 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase |
US6649362B2 (en) | 1997-09-08 | 2003-11-18 | Medvet Science Pty. Ltd. | Screening method for an agent having an effect on a sphingosine kinase signaling pathway |
DE69835223T2 (de) | 1997-09-11 | 2007-05-31 | Takara Bio Inc., Otsu | Sphingosinderivate und medizinische zubereitung |
US6423527B1 (en) | 1997-09-29 | 2002-07-23 | Children's Hospital Medical Center Of Northern California | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
US6057126A (en) | 1997-12-24 | 2000-05-02 | Allelix Biopharmaceuticals, Inc. | Mammalian EDG-5 receptor homologs |
JP2002501751A (ja) | 1998-01-29 | 2002-01-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規化合物 |
EP1053243B1 (en) | 1998-02-12 | 2011-03-30 | Emory University | Sphingolipid derivatives and their methods of use |
WO1999041265A1 (en) | 1998-02-16 | 1999-08-19 | The Kitasato Institute | Novel substances kf-1040 and process for producing the same |
JP2002505868A (ja) | 1998-03-09 | 2002-02-26 | スミスクライン・ビーチャム・コーポレイション | ヒトEDG−1cポリヌクレオチドおよびポリペプチドおよびその使用法 |
EP1071458A4 (en) | 1998-03-13 | 2005-02-16 | Dana Farber Cancer Inst Inc | HUMANIZED ANTIBODIES AND ITS USES |
US6130067A (en) | 1998-05-20 | 2000-10-10 | Smithkline Beecham Corporation | Human EDG3sb gene |
CA2329124A1 (en) | 1998-05-26 | 1999-12-02 | Office Of The Dean Of Research And Graduate Education | Sphingosine kinase, cloning, expression and methods of use |
DE19828850A1 (de) | 1998-06-27 | 1999-12-30 | Gvs Ges Fuer Erwerb Und Verwer | Sphingolipid-Desaturase |
BR9912501A (pt) | 1998-06-29 | 2001-05-02 | Los Angeles Childrens Hospital | Tratamento de distúrbios hiperproliferativos |
DE19847149A1 (de) | 1998-10-13 | 2000-04-20 | Max Planck Gesellschaft | Pseudo-Ceramide |
KR100483494B1 (ko) | 1998-12-01 | 2005-04-15 | 프로테인 디자인 랩스 인코포레이티드 | 감마 인터페론에 대한 인간화 항체 |
DK1140170T3 (da) | 1999-01-05 | 2006-10-23 | Univ Southern Australia | Antistoffragmenter til topisk behandling af öjensygdomme |
AU2899900A (en) | 1999-03-02 | 2000-09-21 | Nps Allelix Corp. | Cloned human sphingosine kinase homologues |
US6812335B1 (en) | 1999-03-23 | 2004-11-02 | The Regents Of The University Of California | Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same |
AU2856499A (en) | 1999-03-25 | 2000-10-16 | Kitasato Institute, The | Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same |
DE60034880T2 (de) | 1999-03-26 | 2008-01-24 | Takara Bio Inc., Otsu | Ceramidasegen |
US7820718B1 (en) | 1999-04-07 | 2010-10-26 | Roger Williams Hospital | Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer |
JP2000293181A (ja) | 1999-04-12 | 2000-10-20 | Daiichikosho Co Ltd | 歌詞画像描出機能に特徴を有するカラオケ装置 |
EP1185559A2 (en) * | 1999-04-28 | 2002-03-13 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
EP1192247B9 (en) | 1999-05-13 | 2007-10-31 | Johnson & Johnson Pharmaceutical Research and Development LLC | Sphingosine kinase enzyme |
DE19924148A1 (de) | 1999-05-26 | 2000-12-07 | Univ Heidelberg | Sphingomyelinasehemmer |
WO2001004139A2 (en) | 1999-07-13 | 2001-01-18 | Smithkline Beecham Corporation | Human axor29 receptor |
IT1307786B1 (it) | 1999-07-22 | 2001-11-19 | Bracco Spa | Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali. |
EP1228221A2 (en) | 1999-10-28 | 2002-08-07 | Warner-Lambert Company | Human sphingosine kinase gene |
WO2001038295A1 (fr) | 1999-11-24 | 2001-05-31 | Taisho Pharmaceutical Co.,Ltd. | Derives de sphingosine |
WO2001055410A2 (en) | 2000-01-28 | 2001-08-02 | Musc Foundation For Research Development | Ceramidase compositions and methods based thereon |
US6667163B2 (en) | 2000-02-07 | 2003-12-23 | Merck & Co., Inc. | Polynucleotide sequences encoding mouse sphingosine-1-phosphate phosphatase |
US6306911B1 (en) | 2000-02-07 | 2001-10-23 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as neutral sphingomyelinase inhibitors |
EP1257637A2 (en) | 2000-02-14 | 2002-11-20 | Curagen Corporation | Sphingosine kinases |
JP2001261575A (ja) | 2000-03-13 | 2001-09-26 | General Hospital Corp | 血管収縮を調節する方法とその組成物 |
AU2001247755A1 (en) | 2000-03-23 | 2001-10-03 | Millennium Pharmaceuticals, Inc. | High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi |
WO2001072701A1 (en) | 2000-03-28 | 2001-10-04 | The Liposome Company, Inc. | Ceramide derivatives and method of use |
AU2001255477A1 (en) | 2000-04-19 | 2001-11-07 | The Trustees Of Columbia University In The City Of New York | Detection and treatment of atherosclerosis based on plasma sphingomyelin concentration |
AUPQ744700A0 (en) | 2000-05-11 | 2000-06-01 | Medvet Science Pty. Ltd. | A method of treatment and agents useful for same |
US6571638B2 (en) | 2000-06-30 | 2003-06-03 | Sawtek, Inc. | Surface-acoustic-wave pressure sensor and associated methods |
US20030125533A1 (en) | 2000-10-06 | 2003-07-03 | Sophia Kossida | Regulation of human sphingosine kinase-like protein |
US6858383B2 (en) | 2000-12-22 | 2005-02-22 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
US20020150582A1 (en) | 2001-02-08 | 2002-10-17 | Friedrichs Gregory S. | Method of treating or inhibiting cellular injury or cell death |
US7674580B2 (en) | 2002-01-17 | 2010-03-09 | Children's Hospital & Research Center At Oakland | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
WO2006014802A2 (en) * | 2004-07-27 | 2006-02-09 | Merck & Co., Inc. | Canis sphingosine 1-phosphate receptor isoform 1 |
PT1812797E (pt) | 2004-10-28 | 2013-05-21 | Lpath Inc | Composições e métodos para o tratamento e prevenção de doenças hiperproliferativas |
WO2006105062A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
US20080213274A1 (en) * | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
US8614103B2 (en) * | 2006-10-27 | 2013-12-24 | Lpath, Inc. | Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions |
-
2007
- 2007-10-26 SI SI200731525T patent/SI2087002T1/sl unknown
- 2007-10-26 EP EP07871262.7A patent/EP2087002B1/en active Active
- 2007-10-26 RU RU2009120052/10A patent/RU2460541C2/ru not_active IP Right Cessation
- 2007-10-26 WO PCT/US2007/082647 patent/WO2008070344A2/en active Search and Examination
- 2007-10-26 BR BRPI0718118A patent/BRPI0718118A2/pt not_active IP Right Cessation
- 2007-10-26 PL PL07871262T patent/PL2087002T3/pl unknown
- 2007-10-26 DK DK07871262.7T patent/DK2087002T3/da active
- 2007-10-26 ZA ZA200902860A patent/ZA200902860B/xx unknown
- 2007-10-26 CN CN201510031165.XA patent/CN104650225B/zh not_active Expired - Fee Related
- 2007-10-26 CA CA002667574A patent/CA2667574A1/en active Pending
- 2007-10-26 AU AU2007329759A patent/AU2007329759B2/en not_active Ceased
- 2007-10-26 JP JP2009534885A patent/JP5795833B2/ja active Active
- 2007-10-26 KR KR1020097010728A patent/KR101581279B1/ko active IP Right Grant
- 2007-10-26 MX MX2009004532A patent/MX2009004532A/es active IP Right Grant
- 2007-10-26 CN CN200780048665.8A patent/CN101679506B/zh not_active Expired - Fee Related
- 2007-10-26 ES ES07871262.7T patent/ES2524059T3/es active Active
- 2007-10-26 PT PT78712627T patent/PT2087002E/pt unknown
- 2007-10-26 US US11/924,890 patent/US7829674B2/en not_active Expired - Fee Related
-
2008
- 2008-10-24 US US12/258,353 patent/US7956173B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/258,337 patent/US8067549B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/258,383 patent/US8026342B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/258,346 patent/US8222373B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/258,355 patent/US8025877B2/en not_active Expired - Fee Related
-
2009
- 2009-04-26 IL IL198379A patent/IL198379A/en not_active IP Right Cessation
-
2015
- 2015-01-13 JP JP2015004493A patent/JP6053834B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
WO2009112245A9 (en) | Antibody against the csf-1 r | |
SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
WO2010032059A3 (en) | Antibodies directed to cd105 and uses thereof | |
MY149630A (en) | Antibodies against amyloid-beta peptide | |
MX347020B (es) | Anticuerpo contra el csf-1r. | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
WO2009128963A3 (en) | Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof | |
WO2008116219A3 (en) | Uses of monoclonal antibody 8h9 | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
MY153710A (en) | Humanized c-kit antibody | |
UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
NZ586754A (en) | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof | |
MX2009006891A (es) | Anticuerpos cd44. | |
AU2016219704A1 (en) | Anti-Notch1 antibodies | |
WO2011004028A3 (en) | Tlr3 binding agents | |
MX2012002458A (es) | Anticuerpos anti-cdcp1 humanizados. | |
WO2008097439A3 (en) | Anti-autoimmune antibodies for treatment of pemphigus | |
MX2009006034A (es) | Anticuerpos antagonistas contra ephb3. | |
MX2009004167A (es) | Anticuerpos que enlazan epitopos cxcr7. | |
MY173526A (en) | Novel anti-?5?1 antibodies and uses thereof | |
MX2010004615A (es) | Anticuerpos monoclonales contra proteina c. activada e inactivada. | |
TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |